Sonoma pharmaceuticals receives new fda 510(k) clearance for microcyn(r)-based wound care hydrogel

Boulder, co / accesswire / november 11, 2024 / sonoma pharmaceuticals, inc. (nasdaq:snoa), a global healthcare leader developing and producing patented microcyn® technology based stabilized hypochlorous acid (hocl) products for a wide range of applications, including wound care, eye, oral and nasal care, dermatological conditions, podiatry, and animal health care, today announced it has received a new 510(k) clearance from the u.s. food and drug administration (fda) for its microcyn technology-based hydrogel, including improved biocompatibility and extended shelf life. per this new clearance, sonoma's microdacyn® hydrogel can be used under the supervision of a healthcare professional for management of wounds associated with dermal irritation, sores, injuries and ulcers of dermal tissue, for use on first and second degree burns, and diabetic ulcers, and for the management of mechanically or surgically debrided wounds.
SNOA Ratings Summary
SNOA Quant Ranking